ImStem Biotechnology Appoints Ernst Zwikker, CPA, as Chief Financial Officer
Farmington, CT. – ImStem Biotechnology (hereafter, ImStem) today announced the appointment of Ernst Zwikker, CPA, as Chief Financial Officer. Mr. Zwikker brings more than 25 years of experience in finance and accounting. He also held leadership and finance and accounting roles at publicly-traded companies PureTech Health and Pfizer. As an experienced finance and accounting executive joining ImStem’s strong leadership team, Ernst will be a core member of the company’s public offering project.
ImStem is an innovative biotech company developing stem cell therapeutic product derived from human pluripotent stem cells (hESC or iPSC) for autoimmune disease, genetic disease, inflammatory disease, and degenerative disease.
“Ernst’s extensive track record in finance and accounting for public biotech, and Nasdaq IPO of biotech company will be very helpful as we are poised to build on the momentum of the past year,” said Michael Men, M.D, Chairman and co-founder of ImStem. “This is an important moment for ImStem, as we recently started a Phase I/IIa clinical trial and dosed the first US multiple sclerosis patients with our leading investigational drug candidate IMS001.” “We are excited to welcome Ernst to the ImStem team and look
forward to his contributions.”
Mr. Zwikker joins ImStem from PureTech Health, where he served as Vice President, Corporate Controller and was involved in the listing on the Nasdaq Stock Market. Prior to this role, Mr. Zwikker worked as Global Corporate Controller for private equity backed company, Candela Medical with responsibility for rebuilding the accounting function. Mr. Zwikker held several roles in external financial reporting, corporate accounting and consolidations for Pfizer, World Fuel Services, and Hitachi. Mr. Zwikker is a CPA who started his career with Arthur Andersen. He holds a MS in Accounting from the University of Connecticut.
“ImStem has established a leadership position in the development of commercially scalable and efficacious hESC-MSC therapy for treatment of multiple sclerosis and other diseases,” said Mr. Zwikker. “I am thrilled to join at this pivotal moment of growth with further key clinical trial readouts anticipated in the next year.”